Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III 
DEB study.

share Share more_vert article Abstract Details First Author Weili Zhao Meeting 2024 ASCO Annual Meeting Session Type Oral Abstract Session Session Title Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Track Hematologic Malignancies Sub Track Non-Hodgkin Lymphoma Clinical Trial Registration Number NCT04231448 Citation J Clin Oncol 42, 2024 (suppl 17; abstr LBA7003) Abstract \# LBA7003 Authors Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China info_outline Weili Zhao, Jun Zhu, Yuqin Song, Peng-Peng Xu, Jianzhen Shen, Qingqing Cai, Hui Zhou, Liling Zhang, Ying Xiang, Xiuhua Sun, Wei Yang, Zhihua Yao, Hongmei Jing, Shujuan Wen, Jie Jin, Hongwei Xue, Hong Cen, Kaiyang Ding, Zhengming Jin, Xiaojing Xing Organizations Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China, Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, China, Fuijian Medical University Union Hospital, Fuzhou, China, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China, Department of Lymphoma & Hematology, Hunan Cancer Hospital, Changsha, China, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Chongqing University Cancer Hospital, Chongqing, China, The Second Hospital of Dalian Medical University, Dalian, China, Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, China, Lymphatic Comprehensive Internal Medicine Ward, Henan Cancer Hospital, Zhengzhou, China, Peking University Third Hospital, Beijing, China, Xinjiang Medical University Affiliated Tumor Hospital, Wulumuqi, China, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, China, The Affiliated Hospital of Qingdao University, Qingdao, China, Department of Medical Oncology, Guangxi Medical University Affiliated Tumor Hospital, Nanning, China, The First Affiliated Hospital of USTC, Hefei, China, Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China, Liaoning Cancer Hospital and Institute, Shenyang, China Abstract Disclosures This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org Recommended For You To view items recommended for you, please sign in to your ASCO.org account. Sign In chevron_right